Evidence map›Paper›PMID 29416723›Full record

ArticleOncotarget2018

Wu Peng, Hao Chen, Zhenzhen Zhao, Xuejiao Hu, Yi Zhou, Yingyu Li, Lian Yang, Xuemei Wang, Jiajia Song, Tangyuheng Liu and 5 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. The Assessment ofJournal of asthma and allergy · 2023
    Article
  6. Multiple CD59 Polymorphisms in Chinese Patients withJournal of immunology research · 2023
    Article
  7. Article
  8. Article
  9. Association of theJournal of thoracic disease · 2019
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Wu Peng *Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, P.R. China.
Hao Chen *Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, P.R. China.
Zhenzhen Zhao *Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, P.R. China.
Xuejiao HuDepartment of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, P.R. China.
Yi ZhouDepartment of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, P.R. China.
Yingyu LiDepartment of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, P.R. China.
Lian YangDepartment of Laboratory Medicine, Chengdu Women and Children's Central Hospital, Chengdu 610091, P.R. China.
Xuemei WangDepartment of Laboratory Medicine, Chengdu Women and Children's Central Hospital, Chengdu 610091, P.R. China.
Jiajia SongDepartment of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, P.R. China.
Tangyuheng LiuDepartment of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, P.R. China.
Qian WuDepartment of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, P.R. China.
Hao BaiDepartment of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, P.R. China.
Xiaojun LuDepartment of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, P.R. China.
Jie ChenDepartment of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, P.R. China.
Binwu YingDepartment of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, P.R. China.
West China Hospital of Sichuan University · CNSichuan University · CNChengdu Women's and Children's Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundObtaining further knowledge regarding single nucleotide polymorphisms in the Toll-like receptor1 gene is of great importance to elucidate immunopathogenesis and management of tuberculosis.

resultsRs5743565 and rs5743557 were significantly associated with reduced predisposition to TB regarding the mutant allele in additive and dominant models with odds ratios (ORs) ranging from 0.61 to 0.83. There was increased tuberculosis risk associated with the haplotype CAG (rs4833095/rs76600635/rs5743596) [OR (95% CI) = 1.33 (1.07-1.65)] and with haplotype GG (rs56357984/rs5743557) [OR = 1.21 (1.02-1.43)]. The erythrocyte and hemoglobin levels were significantly higher in TB patients with the rs5743557 GG genotype than for AA and/or AG genotype carriers (

conclusionsRs5743565 and rs5743557 in the TLR1 gene may contribute to decreased risk for tuberculosis susceptibility in a Western Chinese population. Rs5743565 and rs76600635 are potential risk factors for adverse reactions to anti-TB drugs.

methodsWe enrolled 646 tuberculosis patients and 475 healthy controls from West China. Six single nucleotide polymorphisms in Toll-like receptor1 gene were genotyped in every individual and were analyzed for their association with tuberculosis susceptibility and clinical presentation. The prospective follow-up was performed to determine whether these single nucleotide polymorphisms are associated with adverse reactions to anti-tuberculosis drugs.

Indexed as

adverse reactionsanti-TB drugssingle nucleotide polymorphismsToll-like receptor 1tuberculosis

Identifiers

PMID29416723
PMCPMC5788591
OpenAlexW2774531937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.